Atsushi Fushimi, Breast Surgeon and Oncologist, Assistant Professor at The Jikei University, shared a post on X:
“ASCO26 preview – HER2+ mBC After T-DXd reshaped 2L+, the question shifts to maintenance, real-world dose modification, and biosimilar access.
- 1053: intracranial efficacy of T-DXd in HER2+/HER2-low CNS-involved mBC (systematic review and meta-analysis). The brain question. https://asco.org/abstracts-presentations/261267
- 1106 ADAPT-T-DXd: multi-institutional real-world study of dose-adapted T-DXd in HER2+/low mBC.”
HER2-Positive Breast Cancer: From Fear to a Story of Hope
